| Document |
Document Title |
|
WO/2013/070961 |
Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette ("ABC") transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regu...
|
|
WO/2013/071010 |
The present invention relates to pharmaceutical compositions comprising 4-pregenen-11-17-21-triol-3,20-dione derivatives, and their use as pharmaceuticals as modulators of the glucocorticoid receptors (GR) and/or the mineralocorticoid re...
|
|
WO/2013/068306 |
The invention relates to a compound of formula (I), wherein A, R1 and R2 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament as agonists of the cannabinoid receptor 2.
|
|
WO/2013/071009 |
The present invention relates to novel 4-pregenen-11-17-21-triol-3,20-dione derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals, as modulators of glucocorticoid or miner...
|
|
WO/2013/071203 |
The present invention relates to novel 2,5-dioxoimidazolidin-l-yl-3- phenylurea derivatives of formula I, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-f...
|
|
WO/2013/068876 |
The present invention relates to use of a fixed dose combination comprising Azelastine or its pharmaceutically acceptable salts thereof and Cromolyn or its pharmaceutically acceptable salts thereof for the treatment of ocular allergy. Th...
|
|
WO/2013/070821 |
Disclosed herein are compositions and methods of use thereof for treating diseases, disorders and injuries of the nervous system, com¬ prising a combination of a RTP801 or RTP801L inhibitor, and a Casp2 inhibitor.
|
|
WO/2013/070600 |
The present invention relates to novel aryl urea derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor like-1 (FPRL-1) recep...
|
|
WO/2013/067076 |
Disclosed herein are methods and kits useful for providing neuroprotection to neurons in the inner ear and to methods of treating inner ear diseases and disorders, including tinnitus and Mnire's disease.
|
|
WO/2013/065720 |
The present invention provides an ophthalmological aqueous composition containing (A) a terpenoid, (B) zinc chloride, and (C) at least one type selected from a group consisting of a cellulose polymer compound, a vinyl polymer compound, p...
|
|
WO/2013/065866 |
The present invention provides a combination of rebamipide and a tear-retaining agent as a medicament for the treatment of anterior eye diseases.
|
|
WO/2013/065719 |
The present invention provides an ophthalmological aqueous composition containing a terpenoid and zinc chloride, and having a pH of 7 or more. This ophthalmological aqueous composition: is capable of suppressing a decrease over the long ...
|
|
WO/2013/060020 |
Provided are a polypeptide for preventing and inhibiting neovascularization, and an application thereof. Also provided are a preparation method for the polypeptide, and a pharmaceutical composition containing the polypeptide. The polypep...
|
|
WO/2013/062947 |
The present invention relates to novel amide derivatives of N-urea substituted amino acids, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide ...
|
|
WO/2013/062843 |
The present invention relates to organic molecules of formula (I) capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
|
|
WO/2013/060303 |
Provided are polypeptides for inhibiting angiogenic activity, the source of said polypeptides being placental growth factor-1. Also provided are derivatives of the polypeptides, nucleic acid molecules for encoding same, a pharmaceutical ...
|
|
WO/2013/063269 |
|
|
WO/2013/061269 |
The present invention relates to use of a fixed dose combination comprising Loteprednol or its pharmaceutically acceptable esters/salts thereof and Olopatadine or its pharmaceutically acceptable salts thereof for the treatment of ocular ...
|
|
WO/2013/061977 |
The present invention pertains to the compound represented by formula (I) (in the formula: X1, X2, X3, X4, X5, R5, R6, R7, R8, n, p, q, ring A, and ring B have the same meaning as the definitions described in the description) or a pharma...
|
|
WO/2013/060908 |
The invention relates to the reduction of intraocular pressure by means of a melatonin analogue. The present invention describes a method for reducing intraocular pressure by administering a pharmaceutical formulation of the commercially...
|
|
WO/2013/058258 |
[Problem] To provide a compound useful as the active ingredient in a drug composition for treating diseases to which 11β-hydroxysteroid dehydrogenase type 1 contributes such as dementia, schizophrenia, depression, pain (particularly neu...
|
|
WO/2013/058303 |
The present invention provides a medicinal composition capable of preventing a decrease in the blood exposure level of a third generation coxib drug, a method for preparing the composition and utilization of the same. It was discovered t...
|
|
WO/2013/057183 |
A treatment method for controlling vascularization in a patient's eye or skin includes administering to the patient's eye or skin a pharmaceutical composition having formula (I) or a pharmaceutically acceptable salt, hydrate, enantiomer,...
|
|
WO/2013/058579 |
The present invention relates to a compound of Formula 1, and an SIRT 1 activator including, as an active ingredient, derivatives thereof or pharmaceutically acceptable salts thereof. The present invention also relates to a composition i...
|
|
WO/2013/055073 |
The present invention relates to an ophthalmic composition containing cyclosporine as an active ingredient and comprising propylene glycol, a surfactant, and purified water, and to a method for preparing same. The ophthalmic composition ...
|
|
WO/2013/055540 |
Compositions and methods for treating and/or preventing bacterial infections in animals such as bovines are provided. The compositions and methods utilize the predatory bacterium Bdellovibrio bacteriovorus to treat and/or prevent infecti...
|
|
WO/2013/053856 |
The present invention relates to pharmaceutical compositions comprising hydrogel-linked prodrug for use in the treatment, prevention and/or diagnosis a condition of the eye and ophthalmic devices comprising said pharmaceutical compositions.
|
|
WO/2013/054330 |
The present invention provides foamable pharmaceutical compositions comprising water-soluble antibiotics and anti-inflammatory steroids and methods of preparing same. Particularly, the present invention relates to oil-free pharmaceutical...
|
|
WO/2013/055998 |
The invention provides anti-HtrA1 antibodies and methods of using the same.
|
|
WO/2013/051722 |
The purpose of the present invention is to provide: a method for producing a corneal endothelial cell, particularly from a neural crest stem cell originated from a parenchyma of cornea or an iPS cell, with high efficiency; a method for p...
|
|
WO/2013/051904 |
The present invention relates to a composition for delaying, preventing and treating age-related macular degeneration, wherein the composition comprises ginseng/red ginseng extracts and ginsenoside as an active ingredient. More particula...
|
|
WO/2013/051435 |
[Problem] To provide: a therapeutic agent for eosinophilic sinusitis and eosinophilic otitis media; a gene therapy agent; and a method for preventing the invasion of an eosinophil. [Solution] A therapeutic agent which can be used for the...
|
|
WO/2013/052760 |
The present invention relates to ophthalmic compositions and methods useful to treat dry eye, or to diagnose, cure, mitigate, treat, or prevent dry eye syndrome in man or other animals.
|
|
WO/2013/044736 |
Traditional Chinese medicine composition for external use in treating xerophthalmia and preparation method thereof, wherein the raw material of the traditional Chinese medicine composition consists of Radix Scutellariae, Herba Menthae, R...
|
|
WO/2013/044362 |
The present invention provides new compounds and methods for treating a disease responsive to inhibition of kinase activity, for example a disease responsive to inhibition of protein tyrosine kinase activity, for example a disease respon...
|
|
WO/2013/045694 |
The present invention is directed to compositions and methods for the treatment of degenerative retinal conditions. According to a general aspect, the present invention is directed to inflammatory mediators, preferably components or subs...
|
|
WO/2013/047567 |
Flavin adenine dinucleotide or a salt thereof significantly curbs the decline in viable cell count of corneal epithelial cells induced by ultraviolet radiation, and thus can act as an inhibitor of corneal epithelial cell death induced by...
|
|
WO/2013/047568 |
An inhibitor for corneal epithelial cell death induced by ultraviolet irradiation and/or dryness, the inhibitor dramatically inhibits the decline of the number of living cells in corneal epithelial cells induced by ultraviolet irradiatio...
|
|
WO/2013/044361 |
The present invention provides new compounds and methods for treating a disease responsive to inhibition of kinase activity, for example a disease responsive to inhibition of protein tyrosine kinase activity, for example a disease respon...
|
|
WO/2013/044360 |
The present invention provides new compounds and methods for treating a disease responsive to inhibition of kinase activity, for example a disease responsive to inhibition of protein tyrosine kinase activity, for example a disease respon...
|
|
WO/2013/042684 |
The purpose of the present invention is to provide a prophylactic and therapeutic agent for neurological diseases, said agent comprising as an active ingredient apolipoprotein E-containing lipoproteins or having as an action mechanism a ...
|
|
WO/2013/041810 |
The invention relates to a stable composition for ophthalmic dying, suitable for sterilization in an autoclave, comprising the following in an aqueous solution: - at least a dye, - at least a water-soluble polyol with formula H(HCOH)nH, ...
|
|
WO/2013/040801 |
Provided in the present invention is a hydroxamic acid compound containing quinolyl as shown in formula (I), at the same time also disclosed is the preparation method of the compound and the use thereof, and a drug containing the hydroxa...
|
|
WO/2013/039140 |
The present invention pertains to a compound or a pharmacologically acceptable salt thereof, which has an excellent diglyceride acyltransferase (DGAT) inhibitory effect and an anorectic effect. The compound or pharmacologically acceptabl...
|
|
WO/2013/037479 |
The present invention relates to a composition comprising at least one analogue of prostaglandin as active compound, and a stabilizing amount of at least one hyaluronic acid or a salt thereof, said composition being preservative-free; an...
|
|
WO/2013/037794 |
Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), or a salt or an ester thereof, are provided for use in the treatment and/or prophylaxis of a condition selected from macular oedema, conditions causing damage to retinal photore...
|
|
WO/2013/038195 |
This invention relates to the use of nanoparticles of glucocorticoid antagonists for the treatment of ocular and non-ocular conditions, compositions containing them and methods for the preparation thereof.
|
|
WO/2013/035861 |
A method for determining susceptibility to age-related macular degeneration comprising a step for determining the type of the 238th base from the 5'-end to the 3'-end of the LOC389641 gene contained in a sample from a subject. If the ...
|
|
WO/2013/035837 |
Disclosed is a novel means for suppressing decrease over time in the viscosity of an aqueous liquid agent which contains hyaluronic acid or a pharmaceutically acceptable salt thereof. The means includes a method for suppressing decrease ...
|
|
WO/2013/036105 |
The present invention relates to the fields of medicine and immunology. In particular, it relates to novel antisense oligonucleotides that may be used in the treatment, prevention and/or delay of Leber congenital amaurosis.
|
